JAK inhibitors, particularly AbbVie’s Rinvoq, are gaining significant traction in both early and later line treatments for ulcerative colitis in the US, challenging established therapies and reshaping the treatment landscape. The recent expansion of the ulcerative colitis (UC) treatment market introduced four new options, including Eli Lilly’s Omvoh and Pfizer’s Velsipity, alongside subcutaneous formulations of Entyvio and infliximab.
Despite the dominance of anti-TNF therapies and Entyvio in first-line UC treatment, JAK inhibitors are increasingly being used in second and later lines, with Rinvoq showing strong efficacy. The oral formulation of JAK inhibitors, shared with Zeposia and Velsipity, is a likely driver for their adoption, with Rinvoq’s efficacy profile particularly compelling. The emerging dynamic in UC treatment may be further influenced by new entrants like Omvoh and Velsipity, challenging JAKs and other existing therapies across treatment lines.